Link to full Article Micro-encapsulation may sound like something that only matters for the highly scientifically-literate. But in a competitive market like infant formula it could make a big difference. Stockhead spoke with both sides of a deal completed last week over this trend. It involves venture capitalists BioScience Managers, which invested $5.5 million in […]
Melbourne, Australia and London, UK 8 August 2019 – BioScience Managers (BSM), one of Australia’s leading international healthcare investment firms, today announces an investment in Sydney-based nutrition technology company, Pharmamark Nutrition Pty. Ltd. BSM has invested A$5.5 million in Pharmamark Nutrition. The funds will go toward the development of CSIRO’s microencapsulation technology for Pharmamark’s IntEncap™ product […]
Link to Full Article BioScience Managers (BSM) is one of Australia’s leading international healthcare investment firms. The CSIRO is Australia’s most loved, respected and revered science and research organisation, responsible for fast Wi-Fi, Aerogard and polymer banknotes among many other notable discoveries. Currently it is working on the first gravitational waves in space, growing gluten-free […]
DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]
DUBLIN, Ireland and MELBOURNE, Australia, May 11, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015. Dr. Horn most […]
DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 (GLOBE NEWSWIRE) — Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and nine month periods ended March 31, 2015. Link here. Corporate Highlights In February 2015, we closed our initial public offering of 4.0 million ordinary shares at a price to […]
DUBLIN, Ireland and MELBOURNE, Australia, April 1, 2015 (GLOBE NEWSWIRE) — Link here. Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced it has appointed former Division Head of Novartis Animal Health Dr. George Gunn as non-executive chairman of the Nexvet Board of Directors. The appointment is effective from 31 March 2015. Until January 2015, Dr. Gunn […]
By Renaissance Capital, December 30, 2014 Link here. Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering. The Dublin, Ireland-based company, which was founded in 2010, plans to list on the NASDAQ […]
December 2014 – link here.
DUBLIN, Ireland; MELBOURNE, Australia –‐ December 3, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the signing of a ten year collaboration and distribution agreement with Virbac (EPA:VIRP), one of the largest animal health dedicated companies in the world. Under the terms of the agreement, Virbac will distribute NV-01, Nexvet’s most advanced product, […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: